Cooper, Sally-Ann, Caslake, Muriel, Evans, Jonathan, Hassiotis, Angela, Jahoda, Andrew, McConnachie, Alex, Morrison, Jill, Ring, Howard, Starr, John, Stiles, Ciara, Sullivan, Frank

Background: Early-onset dementia is common in Down syndrome adults, who have trisomy 21. The amyloid precursor protein gene is on chromosome 21, and so is over-expressed in Down syndrome, leading to amyloid β (Aβ) over-production, a major upstream pathway leading to Alzheimer disease (AD). Statins (microsomal 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors), have pleiotropic effects including […]

Serrano-Pozo, Alberto, Vega, Gloria L., Lütjohann, Dieter, Locascio, Joseph J., Tennis, Marsha K., Deng, Amy, Atri, Alireza, Hyman, Bradley T., Irizarry, Michael C., Growdon, John H.

Preclinical and epidemiologic studies suggest a protective effect of statins on Alzheimer disease (AD). Experimental evidence indicates that some statins can cross the blood-brain barrier, alter brain cholesterol metabolism, and may ultimately decrease the production of amyloid-beta (Abeta) peptide. Despite these promising leads, clinical trials have yielded inconsistent results regarding the benefits of statin treatment […]

Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., Aisen, P. S.

Background: Lowering cholesterol is associated with reduced CNS amyloid deposition and increased dietary cholesterol increases amyloid accumulation in animal studies. Epidemiologic data suggest that use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) may decrease the risk of Alzheimer disease (AD) and a single-site trial suggested possible benefit in cognition with statin treatment in AD, […]